Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib + Paclitaxel + Trastuzumab + Pertuzumab in HER2+ Metastatic Breast Cancer
NCT02060253Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganetespib in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Apr 2014; status: completed.
02
Drugs
ganetespib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02060253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060253.